In CLL, in vitro and xenograft murine models have demonstrated a pro-tumor effect of the CD4+ T cell compartment in patients, with correlations of CD4+ subset counts and clinical outcome supporting this role (28, 30). This evidence concerns the gene CD4 and neoplasm.